Antibodies.com Appoints CEO
Dr Claire Button, CEO, antibodies.com
Life science research tools one-stop shop, antibodies.com, has appointed Dr Claire Button as its CEO to develop and execute its global growth strategy.
Button most recently founded Fusion Biomed, a specialist life science investment and executive search firm, partnering with early stage ventures as a strategic advisor. With a PhD in Immunopharmacology, she combines her scientific background with extensive sector knowledge, commercial understanding and a global network. She has advised business owners, shareholders, boards and C-level executives on growth and value realisation during her 10-year career working with high-growth life science companies.
Button’s appointment brings to antibodies.com her knowledge of growing early stage life science businesses into global companies through a focus on customers, securing investment and market understanding.
Antibodies.com has quickly become established as a major supplier of life science research tools, partnering with the world's leading primary manufacturers. Founded by scientists who understand the stringent requirements demanded by researchers, the company provides high-quality and validated antibodies, proteins and assays for life science research.
Referring to the appointment, antibodies.com founder Stewart Newlove said, “We are very excited about Claire’s appointment. Her strategic experience with high-growth ventures, coupled with her global network and sector knowledge, will enable us to move towards rapid market share growth”.
“antibodies.com is at a really exciting stage of growth and offers a great opportunity to build a world-class company that works to truly understand and support it’s customers. Our ethos of lowering price, whilst maintaining quality, enable antibodies.com’s customers to discover more for less. We are now expanding our global offering, including hard-to-source, non-standardised products, across the EU, US and China markets”, explained Button.
“I am delighted to be working alongside our experienced team, including our lead Investor and SEO experts, dedicated to supporting life science research”, Button continued.
UT Southwestern researchers have succeeded in neutralizing what they believe is a primary factor in late-onset Alzheimer’s disease, opening the door to development of a drug that could be administered before age 40, and taken for life, to potentially prevent the disease in 50 to 80 percent of at-risk adults.READ MORE